Israeli co Enlivex Therapeutics raises $8m
The financing led by Korea Investment Partners will fund Phase III clinical trials of the Jerusalem company's lead compound for the prevention of Graft Vs Host Disease (GVHD).
Teva appoints Kare Schultz CEO
Schultz is currently CEO of H. Lundbeck. He will be based at Teva's Petah Tikva headquarters. Teva's share price is up sharply.